First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment

seekingalpha2022-07-19

IvelinRadkov/iStock via Getty Images Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2252976227?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2022-07-19 22:01","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2252976227","market":"us","top_or_hot":-1,"title":"First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment","media":"seekingalpha","content":"<div>\n<p>IvelinRadkov/iStock via Getty Images   Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout ...</p>\n\n<a href=\"https://seekingalpha.com/news/3858089-first-two-cohorts-enrolled-in-allenas-phase-2a-trial-of-gout-kidney-disease-treatment\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>First two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFirst two cohorts enrolled in Allena's phase 2a trial of gout & kidney disease treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-07-19 22:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3858089-first-two-cohorts-enrolled-in-allenas-phase-2a-trial-of-gout-kidney-disease-treatment><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>IvelinRadkov/iStock via Getty Images   Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout ...</p>\n\n<a href=\"https://seekingalpha.com/news/3858089-first-two-cohorts-enrolled-in-allenas-phase-2a-trial-of-gout-kidney-disease-treatment\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://seekingalpha.com/news/3858089-first-two-cohorts-enrolled-in-allenas-phase-2a-trial-of-gout-kidney-disease-treatment","article_id":"2252976227","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2252976227","pubTimestamp":1658239269,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"IvelinRadkov/iStock via Getty Images   Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout pa","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技"},"translate_title":"Allena痛风和肾病治疗2A期试验的前两个队列","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNA":1},"content_text":"IvelinRadkov/iStock via Getty Images   Allena Pharmaceuticals (NASDAQ:ALNA) on Tuesday said it had completed enrollment in the first two cohorts of its phase 2a study of its enzyme ALLN-346 in gout patients with stage 2 and stage 3 chronic kidney disease (CKD).  ALNA is planning to enroll up to four cohorts in the mid-stage trial, called Study 202, with each cohort consisting of up to 12 patients. Cohort A of the trial has enrolled seven patients with stage 2, or mild CKD, and cohort B has enrolled 12 patients with stage 3, or moderate CKD. ALNA said safety and efficacy data from the first two cohorts of the study are expected to be available later this quarter. ALNA stock +1.5% to $0.15 in morning trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2252976227"}